| Literature DB >> 36247952 |
Paulius Kamarauskas1, Daniele Conte1.
Abstract
The aim of this paper was to synthesize the findings on salivary marker responses to the different basketball match typologies. An electronic database search of articles published until October 2020 was performed in PubMed, SPORTDiscus, Scopus and Web of Science. Studies were then screened using pre-defined selection criteria and a subsequent assessment of methodological quality was conducted. Articles matching the selection criteria and methodological quality were included in the systematic review. The electronic database search produced 696 articles. After removing 505 duplicates, 191 articles were included for screening. Screening led to 10 articles that met the inclusion criteria. The main findings revealed that playing a basketball match induced a highly stressful condition reflected by increased post-match cortisol levels regardless of season phase (i.e. regular vs. semi-final vs. final matches), match outcome (i.e. winning vs. losing matches) and location (i.e. home vs. away). Different results were found for testosterone, which showed inconsistent outcomes when measured before and after matches. However, an effect of match location on testosterone levels was observed, with higher concentrations before home matches compared to away matches. Finally, playing basketball matches led to an increase in levels of alpha-amylase, a decrease in interleukin-21 and no changes in immunoglobulin A, total protein and brain-derived-neurotrophic factor. The current results provide a detailed description of salivary markers changes in response to different basketball matches, which can help practitioners to have a better understanding of the basketball performance profile.Entities:
Keywords: Cortisol; Hormonal response; Physiological demand; Psychological demand; Testosterone
Year: 2021 PMID: 36247952 PMCID: PMC9536388 DOI: 10.5114/biolsport.2022.107481
Source DB: PubMed Journal: Biol Sport ISSN: 0860-021X Impact factor: 4.606
Search strategy used to locate relevant research articles.
| Variable | Search terms | |
|---|---|---|
| 1. | Salivary markers | (“hormonal response*” OR “salivary cortisol” OR “salivary testosterone” OR “salivary immunoglobulin A” OR “salivary marker*” OR “endocrinology”) |
| 2. | Type of activity | (“game*” OR “match*”) |
| 3. | Basketball | (“basketball”) |
|
| ||
| Salivary markers AND type of activity AND basketball “1 AND 2 AND 3” | ||
Questions of the modified Downs and Black checklist used for the assessment of methodological quality of the included articles.
| Question | |
|---|---|
| No. | Reporting |
|
| Is the hypothesis/aim/objective of the study clearly described? |
|
| Are the main outcomes to be measured clearly described in the Introduction or Methods section? |
|
| Are the characteristics of the patients/subjects included in the study clearly described? |
|
| Are the main findings of the study clearly described? |
|
| Does the study provide estimates of the random variability in the data for the main outcomes? |
|
| Have actual probability values been reported (e.g. 0.035 rather than < 0.05) for the main outcomes except when the probability value is less than 0.001? |
|
| |
|
| Were the subjects asked to participate in the study representative of the entire population from which they were recruited? |
|
| Were those subjects who were prepared to participate representative of the entire population from which they were recruited? |
|
| |
|
| If any of the results of the study were based on “data dredging”, was this made clear? |
|
| In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case control studies, is the time period between the intervention and outcome the same for cases and controls? |
|
| Were the statistical tests used to assess the main outcomes appropriate? |
|
| Were the main outcome measures used accurate (valid and reliable)? |
|
| Was compliance with the intervention/s reliable? |
Types of methodology used to collect saliva samples in the included articles.
| Study | Salivary markers | Stimulated Yes / No | Mouth rinse Yes / No | Dietary restriction time | Collection type | Manufacturer of reagents |
|---|---|---|---|---|---|---|
| Arruda et al. 2018 [ | Cortisol | No | No | 90 min | Spitting | Salimetrics |
| Testosterone | ||||||
| Alpha-amylase | ||||||
| IL-1b cytokine | ||||||
|
| ||||||
| Arruda et al. 2014 [ | Cortisol | No | No | 90 min | Spitting | Salimetrics |
| Testosterone | ||||||
|
| ||||||
| Gonzalez-Bono et al. 1999 [ | Cortisol | Yes | No | n/a | Spitting | ICN (T) OD (C) |
| Testosterone | ||||||
|
| ||||||
| Moreira et al. 2018 [ | Cortisol | No | No | 90 min | Spitting | Salimetrics (C) |
| Brain-derived neurotrophic factor | Abnova (BDNF) | |||||
|
| ||||||
| Moreira et al. 2013 [ | Cortisol | No | No | 120 min | Spitting | |
| Immunoglobulin A | Salimetrics (C; IgA) | |||||
| Interleukin-21 | eBio (IL-21) | |||||
| Total protein | Pierce (TP) | |||||
|
| ||||||
| Moreira et al. 2012(a) [ | Cortisol | No | No | 120 min | Spitting | ALPCO |
| Immunoglobulin A | ||||||
|
| ||||||
| Moreira et al. 2012(b) [ | Cortisol | No | No | 120 min | Spitting | DSL |
|
| ||||||
| Arruda et al. 2019 [ | Testosterone | No | No | 90 min | Spitting | Salimetrics |
|
| ||||||
| Arruda et al. 2017 [ | Cortisol | No | No | 90 min | Spitting | Salimetrics |
| Testosterone | ||||||
|
| ||||||
| Gonzalez-Bono et al. 2000 [ | Testosterone | Yes | No | n/a | Spitting | ICN |
Note. n/a – not available, not provided in article; Salimetrics – Salimetrics LLC, Carlsbad, CA, USA; ICN – ICN Biomedicals, Costa Mesa, CA, USA; OD – Orion Diagnostica, Espoo, Finland; Abnova – Abnova Corporation, Taiwan; eBio – eBioscience, San Diego, CA, USA; Pierce – Pierce Biotechnology, Rockford, Illinois, USA; ALPCO – ALPCO diagnostics, Salem, MA, USA; DSL – Diagnostic Systems Laboratories, INC, Webster, TX, USA; C – cortisol; T – testosterone; IgA – immunoglobulin A; AA – alpha-amylase; IL-1b – IL-1b cytokine; BDNF – brain-derived neurotrophic factor; IL-21 – interleukin-21.
FIG. 1Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram of search strategy.
Results of methodological quality assessment for included articles.
| Study | Downs and Black checklist question number | TOTAL | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reporting | External validity | Internal validity-bias | ||||||||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ||
| Arruda et al. 2018 [ | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | T | 8 |
| Arruda et al. 2014 [ | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | T | 9 |
| Gonzalez-Bono et al. 1999 [ | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Moreira et al. 2018 [ | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Moreira et al. 2013 [ | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | T | 7 |
| Moreira et al. 2012(a) [ | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | T | 10 |
| Moreira et al. 2012(b) [ | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | T | 9 |
| Arruda et al. 2019 [ | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | T | 9 |
| Arruda et al. 2017 [ | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | T | 7 |
| Gonzalez-Bono et al. 2000 [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | T | 9 |
Note. 1 = Yes; 0 = No/Unable to determine; T – non-interventional study.
Characteristics of the participants in included articles.
| Study | Sample size (N) | Level | Sex | Age (years) | Stature (cm) | Body mass (kg) |
|---|---|---|---|---|---|---|
| Final [Initial] | (mean ± SD) | (mean ± SD) | (mean ± SD) | |||
| Arruda et al. 2018 [ | 14 [18] | Elite | Male | |||
| U16 (N = 7) | U16: 15.1 ± 0.3 | U16: 190.3 ± 9.1 | U16: 90.4 ± 15.5 | |||
| U17 (N = 7) | U17: 16.5 ± 0.5 | U17: 191.5 ± 7.2 | U17: 89.7 ± 18.9 | |||
|
| ||||||
| Arruda et al. 2014 [ | 18 [24] | Elite | Male | 17.8 ± 0.4 | 190 ± 10 | 87 ± 8.5 |
|
| ||||||
| Gonzalez-Bono et al. 1999 [ | 16 [21] | Elite | Male | W: 23.63 ± 1.22 | W: 195.78 ± 1.95 | W: 93.04 ± 3.84 |
| Winners (W) | ||||||
| (N = 8) Losers | L: 22.86 ± 1.82 | L: 195.41 ± 2.6 | L: 94.59 ± 3.49 | |||
| (L) (N = 8) | ||||||
|
| ||||||
| Moreira et al. 2018 [ | 24 [33] | Sedentary | Male | |||
| Sedentary adults | adults | |||||
| (S) (N = 12) | Elite | S: 23.0 ± 4.2 | S: n/a | S: n/a B: | ||
| Basketball players | basketball | B: 18.6 ± 0.5 | B: 192.7 ± 7 | 88.9 ± 14.5 | ||
| (B) (N = 12) | players | |||||
|
| ||||||
| Moreira et al. 2013 [ | 20 | Elite | Male | 18.8 ± 0.4 | 192 ± 10 | 87 ± 8 |
|
| ||||||
| Moreira et al. 2012(a) [ | 10 | Elite | Male | 19 ± 0.6 | 193 ± 6 | 87 ± 7 |
|
| ||||||
| Moreira et al. 2012(b) [ | 10 | Elite | Male | 26.4 ± 3.8 | 196 ± 10 | 100 ± 14 |
|
| ||||||
| Arruda et al. 2019 [ | 25 [33] | Elite | Male | |||
| U15 (N = 8) | U15: 14.1 ± 0.3 | U15: 186.6 ± 6.9 | U15: 78.3 ± 12.2 | |||
| U16 (N = 8) | U16: 15.2 ± 0.4 | U16: 191.0 ± 8.1 | U16: 88.9 ± 13.8 | |||
| U17 (N = 9) | U17: 16.5 ± 0.5 | U17: 191.5 ± 7.2 | U17: 89.7 ± 18.9 | |||
|
| ||||||
| Arruda et al. 2017 [ | 12 | Elite | Male | 18.6 ± 0.5 | 192 ± 7 | 88.9 ± 14.5 |
|
| ||||||
| Gonzalez-Bono et al. 2000 [ | 17 | Elite | Male | T1: 21.56 ± 1.16 # | T1: 194.84 ± 2.10 # | T1 : 92.99 ± 3.85 # |
| Team 1 (T1) | ||||||
| (N = 9) Team | T2: 22.0 ± 1.70 # | T2: 193.83 ± 2.76 # | T2: 92.50 ± 3.67 # | |||
| 2 (T2) (N = 8) | ||||||
Note. n/a – not provided;
- average data reported for initial sample size; SD – standard deviation.
– data reported as mean ± SEM (standard error of the mean).
Methodological outcome measures of included articles
| Study | Duration | Type of activity | Frequency of saliva collection | Salivary markers | Coefficient of variation for the assays (%) |
|---|---|---|---|---|---|
| Arruda et al. 2018 [ | 4 matches | Two winning playoff final matches and two winning regular season matches. | Pre- to post-match. | C | C = 4.4 intra |
| T | T = 4.6 intra | ||||
| AA | AA = 2.6 intra | ||||
| IL-1b | IL-1b = 6.7 intra | ||||
|
| |||||
| Arruda et al. 2014 [ | 2 matches | Two teams played against each other twice, playing at home and away facilities. | Pre- to post-match. | C | C = 3.7 intra |
| T | T = 3.2 intra | ||||
|
| |||||
| Gonzalez-Bono et al. 1999 [ | 9 months | Experimental laboratory session in August, December and April and experimental match in December for two teams. | Pre- to post-match and during 3 laboratory sessions. | C | < 5.0 intra & inter |
| T | |||||
|
| |||||
| Moreira et al. 2018 [ | 6 weeks | Basketball players participated in 3 official matches. Sedentary group visited the laboratory 4 times to complete an experimental protocol at 120% of HRVTH for 30 minutes. | Pre- to post-match and experimental exercise. | C | C = 3.6 intra |
| BDNF | BDNF = 8.0 intra | ||||
|
| |||||
| Moreira et al. 2013 [ | 1 match | Two teams, 1st and 2nd place in the Brazilian State Basketball Championship played regular season matches against each other. | Pre- to post-match. | C | C = 4.8 intra |
| IgA | IgA = 6.0 intra | ||||
| IL-21 | IL-21 = 3.2 intra | ||||
| TP | TP = n/a | ||||
|
| |||||
| Moreira et al. 2012(a) [ | 15 weeks | 5 investigated basketball matches: 2 official and 3 training matches. | Pre- to post-match. | C | < 7.0 intra |
| IgA | |||||
|
| |||||
| Moreira et al. 2012(b) [ | 4 weeks | 4 investigated basketball matches: 2 official and 2 simulated matches. | Pre- to post-match. | C | 4.8 intra |
|
| |||||
| Arruda et al. 2019 [ | 6 winning matches | 3 winning semi-final and 3 winning final matches for U15, U16 and U17 teams. | Pre- to post-match. | T | 4.6 intra |
|
| |||||
| Arruda et al. 2017 [ | 9 weeks | Experimental training session and 3 official matches against different level of opponents. | Pre- to post-match and training session | C | C = 3.4 intra |
| T | T = 4.2 intra | ||||
|
| |||||
| Gonzalez-Bono et al. 2000 [ | 2 matches | Two matches against different level opponents. | Pre- to post-match. | T | < 5.0 intra & inter |
Note. n/a – not available and not provided in article; HRVTH – heart rate variability threshold; C – cortisol; T – testosterone; IgA – immunoglobulin A; AA – alpha-amylase; IL-1b – IL-1b cytokine; BDNF – brain-derived neurotrophic factor; IL-21 – interleukin-21.
Effect of basketball matches on salivary marker levels
| Study | Marker | Measures | Concentration (mean ± SD) | Changes |
|---|---|---|---|---|
| Arruda et al. 2018 [ | C | Regular vs. final matches | Not provided | p = 0.36 |
| Pre- to post-match measures | p < 0.001 | |||
| Effect of interaction | p = 0.09 | |||
|
| ||||
| T | Regular vs. final matches | Not provided | p = 0.28 | |
| Pre- to post-match measures | p < 0.001 | |||
| Effect of interaction | p = 0.35 | |||
|
| ||||
| AA | Pre- to post-regular and final matches | Not provided (Increased) | p < 0.001 | |
| Effect of interaction | Not provided | p = 0.58 | ||
| Effect of condition | p = 0.67 | |||
|
| ||||
| IL-1ß | Pre- to post-regular and final matches | Not provided | p = 0.95 | |
| Effect of interaction | p = 0.75 | |||
| Effect of condition | p = 0.57 | |||
|
| ||||
| Arruda et al. 2014 [ | C | Home vs. away matches | Pre-home Pre: 19.5 ± 5.2 nmol/l | p > 0.05 |
| Post-home: 31.4 ± 7.6 nmol/l | ||||
| Pre- to post-matches (home and away) | Pre-away Pre: 19.1 ± 5.7 nmol/l | p < 0.005 | ||
| Post-away: 28.5 ± 9.5 nmol/l | ||||
|
| ||||
| T | Home vs. away matches | Pre-home: 701 ± 146 nmol/l | p > 0.05 | |
| Pre-match: home vs. away | Pre-away: 531 ± 153 nmol/l | p < 0.001 | ||
| Post-match: home vs. away | Post-home: 944 ± 243 nmol/l | p > 0.05 | ||
| Changes from pre- to post-match values | Post-away: 770 ± 257 nmol/l | p < 0.005 | ||
|
| ||||
| Gonzalez-Bono et al. 1999 [ | C | Winners vs. losers (effect of match | Winners: 3.07 ± 1.31 nmol/l | p > 0.05 |
| outcome) | Losers: 1.59 ± 1.15 nmol/l | |||
| Pre- to post-match | Not provided | p < 0.02 | ||
|
| ||||
| T | Winners vs. losers (effect of result) | Not provided | p > 0.05 | |
| Pre- to post-match | W increase: 0.013 ± 0.04 nmol/l | p > 0.05 | ||
| Winners (W) | ||||
| Losers (L) | L decrease: –0.031 ± 1.31 nmol/l | |||
|
| ||||
| Moreira et al. 2018 [ | C | Group effect (Basketball players vs. Sedentary people) | Not provided | p < 0.001 |
| Time effect (Basketball players vs. Sedentary people) | p < 0.001 | |||
| Interaction (Time x Group) | p < 0.001 | |||
|
| ||||
| BDNF | Group effect (Basketball players vs. Sedentary people) | Not provided (Higher in basketball players) | p < 0.001 | |
| Time effect (Basketball players vs. Sedentary people) | p > 0.05 | |||
| Interaction (Time x Group) | p > 0.05 | |||
|
| ||||
| Moreira et al. 2013 [ | C | Pre- to post-official basketball match | Not provided (Increased during the match) | p < 0.05 |
| IgA | Not provided | p > 0.05 | ||
| Secretion rate IgA | Not provided | p > 0.05 | ||
| IL-21 | Not provided (Decreased) | p < 0.05 | ||
| TP | Pre: 1.7 ± 0.8 mg/ml | p = 0.7 | ||
| Post: 1.9 ± 0.9 mg/ml | ||||
|
| ||||
| Moreira et al. 2012(a) [ | C | Pre- to post-official basketball matches | Pre: 6.1 ± 0.8 nmol/l | p < 0.05 |
| Post: 12.7 ± 2.2 nmol/l | ||||
| Pre- to post-training basketball matches | Pre: 4.2 ± 0.7 nmol/l | p > 0.05 | ||
| Post: 4.4 ± 1.0 nmol/l | ||||
| Pre-match levels for official (OM) and training (TM) matches | OM: Pre: 6.1 ± 0.8 nmol/l | p > 0.05 | ||
| TM: 4.2 ± 0.7 nmol/l | ||||
| Post-match levels for official (OM) and training (TM) matches | OM: 12.7 ± 2.2 nmol/l | p < 0.05 | ||
| TM: 4.4 ± 1.0 nmol/L | ||||
|
| ||||
| IgA | Pre- to post-official (OM) and training (TM) matches | Pre-OM: 457 ± 68 ug/ml | p > 0.05 | |
| Post-OM: 552 ± 59 ug/ml | ||||
| Pre-TM: 494 ± 99 ug/ml | ||||
| Post-TM: 635 ± 137 ug/ml | ||||
|
| ||||
| Secretion rate IgA | Pre- to post-official (OM) and training (TM) matches | Pre-OM: 132 ± 30 ug/min | p > 0.05 | |
| Post-OM: 156 ± 26 ug/min | ||||
| Pre-TM: 118 ± 22 ug/min | ||||
| Post-TM: 145 ± 31 ug/min | ||||
|
| ||||
| Moreira et al. 2012(b) [ | C | Pre- to post-simulated matches (SM) | Not provided | p > 0.05 |
| Pre- to post-official matches (OM) | p < 0.01 | |||
| Comparison of pre-OM and pre-SM | p < 0.03 | |||
| Comparison of post-OM and post-SM | p < 0.01 | |||
|
| ||||
| Arruda et al. 2019 [ | T | Pre- to post-semi-final and final matches | Not provided (Increased) | p < 0.001 |
| Semi-final vs. final match | Not provided | p = 0.20 | ||
| Interaction between conditions | p = 0.93 | |||
|
| ||||
| Arruda et al. 2017 [ | C | Time effect (pre- to post-matches) | Not provided (Increased) | p < 0.0001 |
| Condition effect (TS, EM, MM, HM) | Not provided (Increased) | p < 0.0001 | ||
| Pre- to post-all conditions (TS, EM, MM, HM) | Not provided (Increased) | p < 0.05 | ||
| Comparison of pre-match concentrations (TS vs. EM vs. MM. vs. HM) | Not provided (Higher in HM than in TS, EM and MM) | p < 0.05 | ||
| Comparison of post-match concentrations (TS vs. EM vs. MM. vs. HM) | Not provided (Higher in HM than in TS and EM) | p < 0.05 | ||
|
| ||||
| T | Pre-match (EM, MM, HM) vs. pre-control (TS) concentrations | Not provided (Higher before all matches than before control session) | p = 0.008 | |
| Comparison of pre-match concentrations | Not provided | p > 0.05 | ||
|
| ||||
| Gonzalez-Bono et al. 2000 [ | T | Pre-match: T1 vs. T2 | T1 pre-match: 0.078 ± 0.017 nmol/l | p > 0.05 |
| Pre- to post-match for T1 | p < 0.058 | |||
| T1 post-match: 0.116 ± 0.025 nmol/l | ||||
| Pre- to post-match for T2 | T2 pre-match: 0.087 ± 0.009 nmol/l | p < 0.97 | ||
| T2 post-match: 0.087 ± 0.016 nmol/l | ||||
Note.
– data are reported as mean ± SEM (standard error of the mean);
C – cortisol; T – testosterone; AA – alpha-amylase; IL-1ß – interleukin-1ß; BDNF – brain-derived-neurotrophic factor; IgA – immunoglobulin A; IL-21 – interleukin-21; OM – official match; TM – training match; SM – simulated match; TS – training session; EM – easy match; MM – medium match; HM – hard match; T1 – team 1; T2 – team 2.